Infinity Presents Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia at ASCO
June 02, 2013 at 09:19 AM EDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) today announced updated Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in
